At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 615 enrolled
Drug / intervention
AZD9668 +1 moredrug
Likely dose
AZD9668 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60mg AZD9668 Administered Orally Twice Daily to Subjects With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Budesonide/Formoterol
In Brief
A Phase 2 clinical trial evaluating AZD9668 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 615 participants across 66 sites in 6 countries.
Detailed Summary
The primary objective is to evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD patients by assessing the effects on lung function and symptoms of COPD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBulgaria, Czechia, Hungary, Poland, Romania, Slovakia
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2009
First PostedDec 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedDec 2, 2009
Enrollment StartNov 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.6 years ago
Interventions
AZD9668drug
2 x 30 mg oral tablets bd for 12 weeks
Placebodrug
2 x matched placebo to oral tablet bd for 12 weeks